Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in the spotlight following the company’s third-quarter earnings and a stark warning to short sellers . During Q3, the company reported a net loss of $20.3...
Cassava Sciences press release ( NASDAQ: SAVA ): Q3 GAAP EPS of -$0.51 beats by $0.08 . Net cash use for operations for full-year 2022 is expected to be approximately $80 to $90 million, consistent with previous guidance. Cash and cash equivalents were $174.7 milli...
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN, Texas, Nov. 07, 2022 (GLOB...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips As I discussed in my last article on Cassava Sciences (NASDAQ: SAVA ), controversy continues to weigh on the performance of SAVA stock. Over the past week, shares in the clinical-stage biotech firm have traded wildly....
Cassava Sciences ( NASDAQ: SAVA ) announced Thursday the submission of a federal lawsuit against those who conducted a “short and distort” campaign targeting the Alzheimer’s drug developer. The company, which advances an experimental Alzheimer’s...
AUSTIN, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individuals who executed a “short and distort” campaign against the Comp...
Summary The Clinical Trials on Alzheimer’s Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen. This conference...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Cassava Sciences (NASDAQ: SAVA ) declined by as much as 12% today but have since recovered to the $35 range, down about 4%. This was most likely attributed to the release of an article by Probes Reporter ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since making some big moves last month Cassava Sciences (NASDAQ: SAVA ) stock has largely traded sideways. Yet while SAVA stock has been acting less wild, don’t blame it on a lack of new developments. As...
CASSAVA SCIENCES INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA CASSAVA SCIENCES INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swic...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...